BTS
CTSO icon

BB&T Securities’s Cytosorbents Corp CTSO Stock Holding History

BB&T Securities’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$129K – 1498
2018
Q3 		$129K Buy
+10,000
New +$125K ﹤0.01% 1531

Other funds holding CTSO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

BB&T Securities's CTSO Position: Q4 2018 in Review

BB&T Securities sold out of Cytosorbents Corp (CTSO) in Q4 2018, closing a stake of 10,000 shares — an estimated $129K sold.

BB&T Securities first reported a position in CTSO in Q3 2018 and held it in 1 quarter. The position peaked at $129K in Q3 2018. 85 funds tracked by Wall St. Rank hold CTSO as of Q4 2018.

  • BB&T Securities reported no remaining Cytosorbents Corp position as of Q4 2018 after selling out during the quarter.
  • BB&T Securities sold 10,000 Cytosorbents Corp shares in Q4 2018, an estimated $129K.
  • BB&T Securities first reported a position in Cytosorbents Corp in Q3 2018 and held it in 1 quarter.
  • BB&T Securities's Cytosorbents Corp position peaked at $129K in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2018.

Based on BB&T Securities's 13F filing for Q4 2018, filed 4 Feb 2019.